Loading…
Lobbying Income
$1.9M
Filings
80
Unique Clients
2
Active Period
2017–2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Lower Costs, More Transparency Act of 2026
2026 · third_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 9393 (Lower Costs, More Transparency Act of 2026) -In support of the Lower Cost, More Transparency Act as this bill will require hospitals, labs, and image providers to make price information publicly available and will help reign in Pharmacy Benefit Managers (PBMs).
Client expense: — · Firm income: $30,000
Matched citations: H.R. 9393
FRONT Act
2026 · second_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
Client expense: — · Firm income: $30,000
Matched citations: S. 2305, S.2305
Medication Affordability and Patent Integrity Act
2026 · second_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
Client expense: — · Firm income: $30,000
Matched citations: S. 2658
Ensuring Timely Access to Generics Act of 2025
2026 · second_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
PROFITS OVER PATIENTS: THE PBM BUSINESS MODEL UNDER SCRUTINY" - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families. 340B In Managing Healthcare Costs for Taft-Hartley Plans - Federal reforms would ensure the 340B program supports patient care without shifting costs on multi=employer health plans. Pending legislation would tighten rules on outpatient versus inpatient pricing, limit certain administrative costs, increase transparency, and add new requirements for 340B hospitals. S. 2658 Medication Affordability and Patent Integrity Act - Opposition to S. 2658 as there is no evidence of a systemic issue needing to be addressed by enacting such burdensome requirements for innovator companies, as well as for the USPTO. S.2305 Biosimilar Red Tape Elimination Act - Opposing S. 2305 as the bill is unnecessary. FDA already has the authority to approve biosimilar interchangeability without requiring switching studies and is exercising that authority in recently approved interchangeable biosimilars. Eliminating these standards will do nothing to improve patient access to biosimilars if they are excluded from coverage by PBMs and Health plans. S. 3014 Ensuring Timely Access to Generics Act of 2025 - Opposing S. 3014 as it would amend Section 505(q) of the FDCA to grant FDA authority to summarily deny 505(q) citizen petitions (about approval of generics, biosimilars, and 505(b)(2) applications) if the Agency determines either that the petition was submitted with the primary purpose of delay or does not on its face raise valid scientific or regulatory issues. The bill is unnecessary given FDA's existing authorities as well as FDA guidance.
Client expense: — · Firm income: $30,000
Matched citations: S. 3014
PBM Price Transparency and Accountability Act
2026 · first_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
S.3345 - PBM Price Transparency and Accountability Act - Support comprehensive reform that addresses the entire healthcare supply chain. PBM practices drive up out-of-pocket costs for union members and working families.
Client expense: — · Firm income: $30,000
Matched citations: S.3345
PBM Reform Act of 2025
2025 · third_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R.4317 (PBM Reform Act) - Asking house members to co-sponsor HR 4317 which would ban spread pricing in Medicaid, boost transparency, delinks PBM compensation in Part D, and strengthens CMS oversight of PBM Contracts. H.R. 5256 (Medicare Access to Rural Anesthesiology of 2023) 340B Access Act - Asking house members to co-sponsor 340B Access Act which would make 340B a true safety-net program for patients by ensuring prescriptions are offered to patients at a discount, update and strengthen eligibility requirements, address standards for 340B child sites and subgrantee eligibility.
Client expense: — · Firm income: $30,000
Matched citations: H.R.4317, HR 4317
340B ACCESS Act
2025 · third_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R.4317 (PBM Reform Act) - Asking house members to co-sponsor HR 4317 which would ban spread pricing in Medicaid, boost transparency, delinks PBM compensation in Part D, and strengthens CMS oversight of PBM Contracts. H.R. 5256 (Medicare Access to Rural Anesthesiology of 2023) 340B Access Act - Asking house members to co-sponsor 340B Access Act which would make 340B a true safety-net program for patients by ensuring prescriptions are offered to patients at a discount, update and strengthen eligibility requirements, address standards for 340B child sites and subgrantee eligibility.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 5256
Protecting Patients Against PBM Abuses Act
2025 · second_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 2880 Protecting Patients Against PBM Abuses Act - Discuss updated jobs study, MFN price control and PBM Reform.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2880
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · first_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 1492 (EPIC Act) - Asking members to co-sponsor HR 1492 which fixes the Inflation Reduction Act's small molecule "pill penalty" to ensure continued R&D investments into small molecule medicines.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1492, HR 1492
Protecting Patients Against PBM Abuses Act
2024 · fourth_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2880
Protecting Patients Against PBM Abuses Act
2024 · third_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2880
DRUG Act
2024 · third_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6283
Biosimilar Red Tape Elimination Act
2024 · third_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
Client expense: — · Firm income: $30,000
Matched citations: S. 2305
Medication Affordability and Patent Integrity Act
2024 · third_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. S. 2305 (Biosimilar Red Tape Elimination Act) -Asking to NOT support this bill. S. 2305 does nothing to address anticompetitve PBM behaviors which block access to low cost biosimilars. S. 2780 (Medication Affordability & Patent Integrity Act) - Asking to NOT support this bill. S. 2780 purports to address a problem that does not exist. would overburden the USPTO; and threatens innovation and global competitiveness by potentially requiring the disclosure of previously confidential trade secrets.
Client expense: — · Firm income: $30,000
Matched citations: S. 2780
Protecting Patients Against PBM Abuses Act
2024 · second_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. Senate Judiciary Committee - Affordable Medication and Competition in the Drug Market - PBM reform and IP Protections - Asking for support for pharmacy benefit manager (PBM) reform and IP Protections.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2880
DRUG Act
2024 · second_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. Senate Judiciary Committee - Affordable Medication and Competition in the Drug Market - PBM reform and IP Protections - Asking for support for pharmacy benefit manager (PBM) reform and IP Protections.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6283
DRUG Act
2024 · first_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
Negative Impacts of Expanding TRIPS - Strongly oppose expanding the TRIPS Waiver as it would endanger American Jobs without improving global health. H.R. 6283 DRUG-ACT - Request to co-sponsor the Drug-Act, vote to move to markup in committee and include in the next spending bill. MARCH-IN Congressional Letter - Asking Congressional Members to sign on to letter to President Biden opposing the recent NIST guidance. Proposed guidance attempts to change the landmark Bayh-Dole Act without the consent of Congress. The draft framework will hamstring U.S. innovation to the advantage of competitors and adversaries.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 6283
No Free TRIPS Act
2023 · fourth_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
No Free TRIPS Act (H.R. 3858) - Strongly oppose expanding the TRIPS Waiver as it would endanger American Jobs without improving global health.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3858
Protecting Patients Against PBM Abuses Act
2023 · third_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
Inflation Reduction Act (IRA) - Opposing Expansion of IRA Bill's Drug Coverage. While understanding the intention to provide wider access to affordable medications, we believe this proposed expansion could have unintended negative consequences on employment with the prescription drug industry. Protecting Patients Against PBM Abuses Act (H.R. 2880) - Urging support of H.R. 2880. 2023 Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) - Oppose legislation to expand upon the recent bipartisan language in the draft to reintroduce the concept of "Reasonable Pricing" requirements.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2880
Reward Work Act
2023 · second_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 830 HELP COPAYS ACT - Urging support of the Help Copays Act to ensure affordable access to life-saving medications for all Americans. Provide relief to patients by capping copayments for prescription drugs. S. 1246 SMART PRICES ACT - Urging opposition to the SMART legislation. The emphasis on price controls for prescription drug price negotiations would have adverse effects on future research, investments, and empllyment opportunites in our country. H.R. 3694 WTO'S Expansion of TRIPS Waivers for Drugs - Urging opposition of the waiver to COVID-19 diagnostic devices and treatments, as many WTO members are proposing, would endanger American jobs without improving global health.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3694
HELP Copays Act
2023 · second_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 830 HELP COPAYS ACT - Urging support of the Help Copays Act to ensure affordable access to life-saving medications for all Americans. Provide relief to patients by capping copayments for prescription drugs. S. 1246 SMART PRICES ACT - Urging opposition to the SMART legislation. The emphasis on price controls for prescription drug price negotiations would have adverse effects on future research, investments, and empllyment opportunites in our country. H.R. 3694 WTO'S Expansion of TRIPS Waivers for Drugs - Urging opposition of the waiver to COVID-19 diagnostic devices and treatments, as many WTO members are proposing, would endanger American jobs without improving global health.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 830
SMART Prices Act
2023 · second_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
H.R. 830 HELP COPAYS ACT - Urging support of the Help Copays Act to ensure affordable access to life-saving medications for all Americans. Provide relief to patients by capping copayments for prescription drugs. S. 1246 SMART PRICES ACT - Urging opposition to the SMART legislation. The emphasis on price controls for prescription drug price negotiations would have adverse effects on future research, investments, and empllyment opportunites in our country. H.R. 3694 WTO'S Expansion of TRIPS Waivers for Drugs - Urging opposition of the waiver to COVID-19 diagnostic devices and treatments, as many WTO members are proposing, would endanger American jobs without improving global health.
Client expense: — · Firm income: $30,000
Matched citations: S. 1246
Prescription Pricing for the People Act of 2023
2023 · first_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
S. 113 Prescription Pricing for the People Act of 2023 S. 127 Pharmacy Benefit Manager Transparency Act of 2023 As a result of their impact on the prices charged to the patient or sponsor, many of the contractual and billing practices of the non-manufacturer links in the drug supply chain provide unnecessary barriers to receiving access to needed prescription drugs. Among others, these impact the participants, dependents, beneficiaries and survivors who receive their health benefits from jointly managed, multiemployer health benefit plans. These realities are in direct conflict with the stated policy positions of PILMA. The proposed Senate bills, S. 113 and S. 127 are both steps in the right direction although modifications and additional provisions that would strengthen the legislation.
Client expense: — · Firm income: $30,000
Matched citations: S. 113
Pharmacy Benefit Manager Transparency Act of 2023
2023 · first_quarter · Client: PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
S. 113 Prescription Pricing for the People Act of 2023 S. 127 Pharmacy Benefit Manager Transparency Act of 2023 As a result of their impact on the prices charged to the patient or sponsor, many of the contractual and billing practices of the non-manufacturer links in the drug supply chain provide unnecessary barriers to receiving access to needed prescription drugs. Among others, these impact the participants, dependents, beneficiaries and survivors who receive their health benefits from jointly managed, multiemployer health benefit plans. These realities are in direct conflict with the stated policy positions of PILMA. The proposed Senate bills, S. 113 and S. 127 are both steps in the right direction although modifications and additional provisions that would strengthen the legislation.
Client expense: — · Firm income: $30,000
Matched citations: S. 127
Infrastructure Investment and Jobs Act
2022 · third_quarter · Client: INT'L. ASSOCIATION OF BRIDGE, STRUCTURAL, ORNAMENTAL & REINFORCING IRON WORKERS
H.R.3684 - Infrastructure Investment and Jobs Act - Fully fund the bill requiring Prevailing Wage.
Client expense: — · Firm income: $20,000
Matched citations: H.R.3684
Source: Senate LDA